A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

NCT04560998 on ClinicalTrials.gov · last registry update 2026-06-05

Finished 5 June 2024, after enrolling 792 people. Primary outcome, as filed: Change in Maximum Walking Distance on a Constant Load Treadmill Test. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 792
Started: 2020-10-01
Primary completion: 2024-06-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Maximum Walking Distance on a Constant Load Treadmill Test

Conditions studied

Diabetes Mellitus, Type 2 · Peripheral Arterial Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.